Compare DFIN & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFIN | TBPH |
|---|---|---|
| Founded | 1983 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2017 | 2013 |
| Metric | DFIN | TBPH |
|---|---|---|
| Price | $46.93 | $15.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $61.50 | $17.80 |
| AVG Volume (30 Days) | 227.2K | ★ 846.4K |
| Earning Date | 04-29-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | 1.15 | ★ 2.06 |
| Revenue | ★ $963,000,000.00 | $15,386,000.00 |
| Revenue This Year | $4.98 | $9.51 |
| Revenue Next Year | $3.87 | N/A |
| P/E Ratio | $40.78 | ★ $7.42 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $37.07 | $7.90 |
| 52 Week High | $66.25 | $21.03 |
| Indicator | DFIN | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 45.85 | 46.28 |
| Support Level | $44.46 | $13.41 |
| Resistance Level | $48.65 | $19.04 |
| Average True Range (ATR) | 1.74 | 0.41 |
| MACD | -0.21 | 0.31 |
| Stochastic Oscillator | 33.56 | 80.00 |
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).